The patent expiration for Dupilumab, marketed as Dupixent, is a significant topic for several reasons, including the potential for generic competition and the drug's therapeutic applications.
When does Dupilumab's market exclusivity end?
Dupilumab is protected by a complex web of patents. While the exact expiration dates for all patents related to Dupilumab are not publicly consolidated, early patent expiries are anticipated. For instance, some Orange Book-listed patents for Dupixent were expected to expire around November 2027, though patent litigation could alter these timelines [1].
How might patent expiration impact Dupixent pricing and availability?
Following patent expiration, the door opens for biosimilar manufacturers to enter the market. Biosimilars are highly similar to their reference biologics and are expected to offer lower prices. This increased competition typically leads to reduced drug costs and greater patient access, as seen with other biologics after their patent cliffs [2].
What is Dupilumab used for?
Dupilumab is a biologic medication used to treat a range of inflammatory conditions. It is approved for moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) [3]. It is also indicated for eosinophilic esophagitis (EoE) and prurigo nodularis [3].
What are the key patents covering Dupilumab?
Dupilumab's patent landscape includes numerous patents covering various aspects of the drug, such as its composition, manufacturing processes, and methods of use for specific indications. The patents identified in the Orange Book by the FDA are critical for understanding market exclusivity. For example, US Patent No. 11,090,465 is among those listed [1].
Are there ongoing legal challenges to Dupilumab's patents?
Yes, patent litigation is common for blockbuster drugs like Dupixent. Companies seeking to market biosimilars often challenge existing patents, arguing they are invalid or not infringed. DrugPatentWatch.com monitors these legal challenges, which can significantly affect the timeline of generic entry [1].
What are other treatments for conditions Dupilumab treats?
For atopic dermatitis, other treatments include topical corticosteroids, calcineurin inhibitors, JAK inhibitors, and other systemic therapies. Asthma treatment can involve inhaled corticosteroids, bronchodilators, and other biologics. Chronic rhinosinusitis with nasal polyposis may be managed with nasal corticosteroids, saline rinses, and surgery, in addition to biologics [3].
Who develops and markets Dupilumab?
Dupilumab is developed and marketed by Regeneron Pharmaceuticals and Sanofi [3].